-- The Thomas Weisel Partners Healthcare Conference in Boston. Mr. Karbe will present at 2:05 p.m. ET/11:05 a.m. PT on Thursday, September 10, 2009.
-- The Morgan Stanley Global Healthcare Conference in New York. Mr. Karbe will present at 11:30 a.m. ET/8:30 a.m. PT on Tuesday, September 15, 2009.
-- The BioCentury Newsmakers in the Biotech Industry Conference in New York. Mr. Karbe will present at 3:00 p.m. ET/12:00 p.m. PT on Wednesday, September 16, 2009.
During each presentation, Mr. Karbe will discuss Exelixis' development pipeline and corporate strategy. Each presentation will be webcast and may be accessed in the Event Calendar page under Investors on the Exelixis website at www.exelixis.com.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech, Boehringer Ingelheim, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.
SOURCE: Exelixis, Inc.
Exelixis, Inc. Investor Contact: Charles Butler, 650-837-7277 Executive Director, Corporate Communications cbutler@exelixis.com or Media Contact: Soleil Maxwell Harrison, 650-837-7012 Senior Manager, Corporate Communications sharrison@exelixis.com

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index